New to peptides? Start with the foundations ->
The dad-test answer
Both are research peptides with no human RCTs. BPC-157 has the deeper animal-study record for gut and tendon healing. TB-500 has stronger animal-study support for systemic soft-tissue and ligament work. Most operators run them together for 4 to 6 weeks rather than choosing - that's the Wolverine Blend.
Who wins for what
| Use case | Who wins, and why |
|---|---|
| tendon and gut healing |
bpc-157 Gwyer et al. 2010 Achilles transection model and Sikiric et al. ulcer studies remain the most-cited animal evidence. |
| ligament, muscle belly, deep soft tissue |
tb-500 Goldstein and Hannappel reviews on Thymosin Beta-4 show stronger systemic actin-binding and angiogenesis evidence for full-thickness tissue. |
| oral bioavailability for gut work |
bpc-157 BPC-157 is stable in stomach acid (it was isolated FROM gastric juice); TB-500 has no oral evidence. |
| speed of effect |
tb-500 Operators report 1-2 week response time on TB-500 loading doses; BPC-157 is typically a 3-4 week protocol. |
What the head-to-head data shows
Neither peptide has FDA approval or human RCTs in 2026, so the evidence is animal data plus a deep biohacker community track record. The foundational BPC-157 paper is Gwyer et al. 2010 (rat Achilles transection model showing accelerated tendon healing). Sikiric et al. 2018 reviews BPC-157's gut-protective and angiogenic mechanisms across decades of rat work. TB-500's evidence sits on Thymosin Beta-4 papers - Goldstein and Hannappel 2012 covers the actin-binding mechanism that drives wound healing and tissue regeneration in animal models. Both molecules are research-use-only chemicals in the US - not FDA-approved, not WADA-legal for competitive athletes (TB-500 is on the WADA prohibited list).
Our honest call
If a reader has to choose one, choose BPC-157 for tendon, gut, and post-surgical work. Choose TB-500 for ligament, muscle belly, or systemic soft-tissue trauma where speed matters. Most operators we trust run them together for 4 to 6 weeks - that combo is the Wolverine Blend. The honest framing: nobody has run a head-to-head human trial on these. The evidence is animal-grade and anecdotal-grade. We have used BPC-157 personally for rotator-cuff recovery and seen the result. We have not personally validated TB-500.
Sources and citations
- Gwyer et al., Achilles tendon repair in BPC-157, J Orthop Res 2010 (PMID 19514371)
- Sikiric et al., BPC-157 angiogenic and gut-protective mechanisms, Curr Pharm Des 2018 (PMID 29427247)
- Goldstein and Hannappel, Thymosin Beta-4 mechanism review, Ann NY Acad Sci 2012 (PMID 22500133)
- WADA Prohibited List 2026 (TB-500 / Thymosin Beta-4)
Where to go next
Subscribe to the dispatch
The weekly Protocol One dispatch covers what's moving in peptides, GLP-1s, and longevity protocols. Free. 5-min read. Broken down for normal humans.
Last reviewed · 2026-05-07 · Page generated by Protocol One matrix engine. None of this replaces a doctor. Peptides are gray-market in the US for most uses. Talk to a real prescriber before you change anything.